Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention

In this crossover study, patients will serve as their own controls. Patients will receive slow-release potassium citrate (UroCit-K), potassium magnesium citrate (powder), or potassium magnesium citrate (tablets). The study period will last approximately 6 weeks for each participant. Patients will be instructed to take one form of potassium citrate for one week at a time followed by a washout period for one week. This process will be completed a total of three times as we seek to study the effects of three forms of potassium citrate.